Targeting a subpocket in Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) enables the structure-based discovery of selective Inhibitors with trypanocidal activity by Blaazer, Antoni R. et al.
Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1
(TbrPDEB1) Enables the Structure-Based Discovery of Selective
Inhibitors with Trypanocidal Activity
Antoni R. Blaazer,†,○ Abhimanyu K. Singh,‡,○ Erik de Heuvel,† Ewald Edink,† Kristina M. Orrling,†
Johan J. N. Veerman,§ Toine van den Bergh,§ Chimed Jansen,† Erin Balasubramaniam,‡ Wouter J. Mooij,†
Hans Custers,† Maarten Sijm,† Daniel N. A. Tagoe,∥ Titilola D. Kalejaiye,∥ Jane C. Munday,∥
Hermann Tenor,⊥ An Matheeussen,# Maikel Wijtmans,† Marco Siderius,† Chris de Graaf,†
Louis Maes,# Harry P. de Koning,∥ David S. Bailey,∇ Geert Jan Sterk,† Iwan J. P. de Esch,†
David G. Brown,*,‡ and Rob Leurs*,†
†Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, 1081
HZ Amsterdam, The Netherlands
‡School of Biosciences, University of Kent, Canterbury CT2 7NJ, U.K.
§Mercachem, 6546 BB Nijmegen, The Netherlands
∥Institute of Infection, Immunity and Inﬂammation, University of Glasgow, Glasgow G12 8TA, U.K.
⊥Topadur Pharma AG, 8952 Schlieren, Switzerland
#Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, 2610 Wilrijk, Belgium
∇IOTA Pharmaceuticals, Cambridge CB4 0WS, U.K.
*S Supporting Information
ABSTRACT: Several trypanosomatid cyclic nucleotide phos-
phodiesterases (PDEs) possess a unique, parasite-speciﬁc cavity
near the ligand-binding region that is referred to as the P-pocket.
One of these enzymes, Trypanosoma brucei PDE B1
(TbrPDEB1), is considered a drug target for the treatment of
African sleeping sickness. Here, we elucidate the molecular
determinants of inhibitor binding and reveal that the P-pocket is
amenable to directed design. By iterative cycles of design,
synthesis, and pharmacological evaluation and by elucidating the
structures of inhibitor-bound TbrPDEB1, hPDE4B, and
hPDE4D complexes, we have developed 4a,5,8,8a-tetrahydroph-
thalazinones as the ﬁrst selective TbrPDEB1 inhibitor series.
Two of these, 8 (NPD-008) and 9 (NPD-039), were potent (Ki
= 100 nM) TbrPDEB1 inhibitors with antitrypanosomal eﬀects (IC50 = 5.5 and 6.7 μM, respectively). Treatment of parasites
with 8 caused an increase in intracellular cyclic adenosine monophosphate (cAMP) levels and severe disruption of T. brucei
cellular organization, chemically validating trypanosomal PDEs as therapeutic targets in trypanosomiasis.
■ INTRODUCTION
The family of trypanosomatids is responsible for three major
neglected tropical diseases (NTDs) caused by protozoan
parasites, namely, Chagas disease (Trypanosoma cruzi),
leishmaniasis (Leishmania spp.), and human African trypano-
somiasis, also called African sleeping sickness (Trypanosoma
brucei rhodesiense and T. brucei gambiense).1 Although millions
of people, mostly in underdeveloped countries, are at risk,
current options for drug treatment of these infectious diseases
remain limited.2
Recently, the inhibition of 3′,5′-cyclic nucleotide phospho-
diesterases (PDEs) has emerged as a new approach to target
these kinetoplastid protozoans.3−6 All three parasites, T. cruzi,
Leishmania spp., and T. brucei spp., have the same set of four
diﬀerent class I PDE families in their genomes.7 Using an
inducible siRNA approach, Seebeck and co-workers demon-
strated that simultaneous inhibition of T. brucei PDE B1
(TbrPDEB1) and TbrPDEB2 blocks parasite proliferation and
eliminates parasitemia from infected mice,8 thereby establishing
the parasite PDEs as promising drug targets.
Subsequent eﬀorts to identify TbrPDEB1 inhibitors have
resulted in the repurposing of ligands that were originally
developed as inhibitors for human PDE4 (hPDE4) as
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TbrPDEB1 inhibitors (Figure 1).9−12 However, until now, all
compounds reported as TbrPDEB1 inhibitors remain more
active on hPDE4. The most potent TbrPDEB1 inhibitor
reported to date, NPD-001 (1), is 10-fold more potent on
hPDE4 (hPDE4B1 IC50 = 0.6 nM) than on TbrPDEB1 (IC50 =
4 nM).11 In a series of analogs of 1 a close correlation between
TbrPDEB1 inhibitory potency and antiparasitic activity has
been found.11 Although these TbrPDEB1 inhibitors raise
cAMP levels in T. brucei and show strong antiparasitic eﬀects
in vitro,10−12 their potent inhibition of hPDE4 is undesir-
able.13−16 Considerable screening and synthetic eﬀorts have
been reported,9−12 but no TbrPDEB1-selective (over hPDEs)
inhibitors have been identiﬁed to date. Despite the high
similarity of hPDE4 and TbrPDEB1 substrate binding
pockets,17 tantalizing evidence for discriminating selectivity is
evident from the observation that established hPDE4 inhibitors
such as rolipram and etazolate do not inhibit either the enzyme
TbrPDEB1 or T. brucei cellular PDE activity and do not kill the
parasite.9,10
In an eﬀort to gain structural understanding to aid in the
design of selective TbrPDEB1 inhibitors, we previously
reported the crystal structure of the apo-TbrPDEB1 catalytic
domain as part of a structure-based virtual screening eﬀort.17
The high-resolution structure of the TbrPDEB1 catalytic
domain revealed an open cavity formed between helix 14
(H14), helix 15 (H15), and the M-loop (Figure 2). This cavity
is also present in the apo structure of related parasite PDEs,
including Leishmania major PDE B1 (LmPDEB1)18 and T.
cruzi PDE C (TcrPDEC),19 but is not present in any of the 11
human PDEs.20,21 Being parasite-speciﬁc, this cavity has been
named the P-pocket. As the most prominent structural
diﬀerence between parasite and human PDE enzymes, the P-
pocket has been considered a promising feature for selective
TbrPDEB1 inhibitor design.17 Molecular docking studies
suggested that the phenyltetrazole-containing tail group of
inhibitors 1 and 2 can interact with residues deep inside the P-
pocket.11,12 However, the preferential inhibition of hPDE4 over
TbrPDEB1 by these compounds is not consistent with this
hypothesis, and therefore the usefulness of targeting the P-
pocket to achieve selectivity remains to be demonstrated.
Here, we present detailed structural insights in TbrPDEB1
ligand binding by reporting the ﬁrst inhibitor-bound
TbrPDEB1 crystal structures, including cocrystal structures
with 1 and 2. These structures clearly explain the lack of
selectivity of the previously reported inhibitors and guide the
design and synthesis of novel P-pocket targeting inhibitors with,
for the ﬁrst time, selectivity over hPDE4B. We show that these
novel compounds inhibit cAMP degradation in T. brucei with
consequent trypanocidal activity.
■ RESULTS AND DISCUSSION
The most potent TbrPDEB1 inhibitor reported to date, NPD-
001 (1), is a nanomolar inhibitor of TbrPDEB1 and a sub-
nanomolar inhibitor of hPDE4 subtypes (IC50 < 1 nM) but is
over 100-fold less active against all other human PDEs.10,11 The
structurally related pyrazolone analogs, such as NPD-340 (2),
are also potent TbrPDEB1 inhibitors, but these too are more
potent at hPDE4.12 Our earlier molecular docking studies
suggested that the central dialkoxyphenyl moiety of 1 and 2
forms a hydrogen bond to the PDE family wide conserved
Gln874Q.50 residue while occupying the hydrophobic clamp,
Figure 1. Representative hPDE4 inhibitors and reported TbrPDEB1 inhibitors.9,10,12
Figure 2. Crystal structure of apo-TbrPDEB1 (PDB code 4I15) active
site highlighting the parasite P-pocket. Helix 14 (H14), helix 15
(H15), and the M-loop are labeled in red, the main binding site
features are labeled in black, water molecules have been omitted for
clarity. The conserved Gln874Q.50, the hydrophobic clamp residues
Val840HC.32 and Phe877HC.52, and the distal aromatic residues
Phe844S.35 and Phe880HC2.54 are shown as sticks. P-pocket residues
Ala837Q1.30, Thr841Q2.33, Tyr845Q2.36, Asn867Q2.43, Met868Q2.44,
Glu869Q2.45, and Leu870Q2.46 are shown as lines. All binding site
residues have been named according to the PDEStrIAn nomenclature
convention.21
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formed by Val840HC.32 and Phe877HC.52 in TbrPDEB1.11,12 In
addition to these hallmark interactions of PDE inhibitor
binding, the docking studies also suggested that 1 and 2 bind
in the P-pocket of TbrPDEB1 with their tetrazole-containing
ﬂexible tail group. The TbrPDEB1 activity of these compounds
is promising, but their even higher potency against hPDE4
seemed inconsistent with successful targeting of the P-pocket as
a means of obtaining selectivity.
In order to gain a better understanding of the lack of
selectivity of these compounds and to guide our ongoing
medicinal chemistry eﬀorts, we obtained the crystal structure of
1 in complex with the catalytic domain of TbrPDEB1 at a
resolution of 1.73 Å (Figure 3a). The overall fold of the protein
was highly similar (rms deviation of Cα = 0.38 Å over 630
atoms) to that observed for the apo structure of TbrPDEB1
(PDB code 4I15). Two protein molecules pack in the crystal
asymmetric unit of TbrPDEB1 where the binding site of one of
the molecules lies close to a symmetry-related molecule. We
refer to the interactions of TbrPDEB1 with ligands at the chain
that is free from such crystal packing eﬀects, unless noted
otherwise. Consistent with biochemical data, 1 was found to
bind in the substrate-binding pocket. The dialkoxyphenyl
moiety of 1 was situated in the hydrophobic clamp formed by
Val840HC.32 and Phe877HC.52, and its two ether functionalities
were within hydrogen bonding distance of the conserved
Gln874Q.50 residue. The (4aS,8aR)-enantiomer of 1 was
observed in the crystal structure. In contrast to the docking
pose suggested by the earlier computational studies,11,12 the tail
group of 1 is oriented away from the P-pocket, with the
tetrazole moiety instead forming a stacking interaction with
Phe880HC2.54 in H15.
The crystal structure of the TbrPDEB1 catalytic domain with
2 was determined at 2.25 Å resolution (Figure 3b).
Compounds 1 and 2 adopted an identical binding mode with
conservation of the key interactions of the catechol and
phenyltetrazole tail with TbrPDEB1.
We also determined the crystal structure of 1 in complex
with hPDE4B (Figure 3c) and hPDE4D (Figure 3d) at 2.4 and
2.25 Å resolution, respectively. As expected, the hPDE4B
structure displayed a similar overall fold to the TbrPDEB1
structure bound to 1 (rms deviation of Cα = 1.26 Å over 247
atoms). In line with its high potency as a hPDE4 inhibitor, 1
was observed in the cAMP-binding site and interacted with
hPDE4B through a bifurcated hydrogen bond to the invariant
Gln615Q.50. As in the TbrPDEB1 structure, there are key
interactions with the hydrophobic clamp, formed by Ile582HC.32
and Phe618HC.52, in addition to a well-positioned stacking
interaction of the tetrazole moiety with Tyr621HC2.54. In the
catalytic domain of hPDE4D the interaction pattern exhibited
by 1 was identical to that observed in the hPDE4B structure. In
all structures, only the single (4aS,8aR)-enantiomer of 1 was
observed. The similar binding mode observed in these
structures unequivocally establish that the tetrazole tail present
in 1 and 2 does not target the P-pocket in TbrPDEB1, which
potentially explains the lack of selectivity of these compounds
for TbrPDEB1 over hPDE4B.
Inspection of the binding site characteristics of TbrPDEB1
and the binding modes observed for 1 and 2 highlighted that
the hydrophobic clamp and the extended hydrophobic region
(HC2) (Figure S1) provide a favorable environment for the
ﬂexible linker of these inhibitors to fold away from the P-pocket
and interact with the aromatic residue found in H15, being
Phe880HC2.54 in TbrPDEB1 and Tyr621HC2.54 in hPDE4B. We
hypothesized that modiﬁcation of the ﬂexible alkyl linker could
prevent such a hydrophobic collapse and utilized the
Phosphodiesterase Structure and Ligand Interaction Annotated
(PDEStrIAn)21 tool for the design of such ligands. More
speciﬁcally, it was observed that some cocrystallized human
PDE inhibitors (for example, PDB codes 3IAD and 4AEL) have
Figure 3. Crystal structures of nonselective inhibitors with TbrPDEB1, hPDE4B, and hPDE4D. (a) TbrPDEB1−1, including |Fo − Fc|αcalc electron
density map contoured at 2.5σ. (b) TbrPDEB1−2. (c) hPDE4B−1. (d) hPDE4D−1. In all panels: key binding site amino acid residues are shown as
sticks, minor amino acid residues are shown as lines. The P-pocket is shown as a gray surface with P-pocket residues represented as lines, and key
polar interactions are depicted with black dashed lines. Water molecules are displayed as red spheres, zinc cations as metallic blue spheres, and
magnesium cations as green spheres.
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a central aromatic moiety bound in the hydrophobic clamp
while having additional (hetero)aryl groups along the vector
that would point toward the P-pocket in TbrPDEB1. It was
hypothesized that replacing the ﬂexible linker at the 3-position
of the dialkoxyphenyl ring of 1 with a phenyl ring would
provide a biphenyl system with the desired rigidity and vector
to target the P-pocket.
Accordingly, we produced an initial series of biphenyl analogs
3−6 and screened them as inhibitors of TbrPDEB1 and
hPDE4B1 (Table 1). Introduction of the biphenyl linker indeed
led to some selectivity for TbrPDEB1 over hPDE4B1 in
carboxylic acids 3 and 4. The TbrPDEB1 selectivity was higher
for the para-substituted 3 over its meta-substituted analog (4).
The potency at TbrPDEB1 increased 10-fold upon introduc-
tion of a carboxamide group at the para-position in compound
5. In accordance with the overlapping pharmacological proﬁles
of hPDE4 subtypes, 5 showed the same potency against all
tested hPDE4s but was selective over the other human PDE
subtypes (Table S5).
These ﬁndings led to further design and synthesis of a series
of para-substituted carboxamide analogs, using 5 as a template
to further improve TbrPDEB1 potency and selectivity over
hPDE4B (Table 2). Extending the carboxamide of 5 with a
methoxyethyl substituent (7) was found to increase the
selectivity for TbrPDEB1 7-fold, while the potency was
comparable to that of its parent compound. Gratifyingly,
glycinamide 8, and its isopropyl-substituted counterpart 9, were
even more potent TbrPDEB1 inhibitors (Ki = 100 nM and 99
nM, respectively). The cycloheptyl-substituted compound 8
displayed 10-fold selectivity over hPDE4B1 and was also
selective over the other hPDE4 subtypes (Table S5). The
potency of 8 was fully explained by the biological activity of a
single enantiomer; (8a) was found to be 100-fold less potent
against TbrPDEB1 than its optical isomer 8b. Both
enantiomers of 8 were selective TbrPDEB1 inhibitors, with
8b showing 16-fold selectivity. Furthermore, isopropyl analog 9
showed a 19-fold preference for TbrPDEB1 over hPDE4B1.
These glycinamide compounds are the most selective
TbrPDEB1 inhibitors reported to date. The introduction of
N-methyl, N,N-dimethyl, or N-isopropyl substituents on
diﬀerent positions of the P-pocket tail (compounds 10−13)
led to decreases in potency as well as selectivity. Alkylation was
least tolerated at the terminal nitrogen (12, 13), indicating that
changes in hydrophobicity or hydrogen bonding properties are
unfavorable. Increasing the chain length of glycinamide 8 with
an additional carbon, to give 14, resulted in a substantial
decrease in potency at TbrPDEB1 but not at hPDE4B1,
decreasing selectivity for TbrPDEB1 to only 2-fold. Inversion of
the carboxamide of 14 aﬀected the hPDE4B1 potency and
restored the TbrPDEB1 selectivity back to 5-fold in compound
15. Finally, further extension of the glycinamide of 8 with a
hydroxyethyl (16) or methoxyethyl (17) substituent was
tolerated and resulted in ∼8 fold selective TbrPDEB1
inhibitors. These ﬁndings highlight that selectivity for
TbrPDEB1 over hPDE4B1 is very sensitive to small changes
in the inhibitor tail group.
In order to validate the P-pocket targeting approach to
selectivity, we obtained the crystal structures of 8 (Figure 4a)
and 9 (Figure 4b) with TbrPDEB1 at a resolution of 1.8 and
2.0 Å, respectively. The overall fold of these structures was
highly similar to the apo-TbrPDEB1 (PDB code 4I15) and the
TbrPDEB1−1 crystal structures (rms deviations of Cα < 0.3
Table 1. Introduction of the Biphenyl Linkera
apKi values are averages (n ≥ 2, with SD less than ±0.3 for all). bCompounds are racemic mixtures of cis-isomers. cSelectivity is calculated as
hPDE4B1 (Ki)/TbrPDEB1 (Ki).
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Table 2. Exploration of SAR in the P-Pocketa
apKi values are averages (n ≥ 2, with SD less than ±0.3 for all). bCompounds are racemic mixtures of cis-isomers unless otherwise noted. cSelectivity
is calculated as hPDE4B1 (Ki)/TbrPDEB1 (Ki).
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Å). Both ligands bonded to the invariant Gln874Q.50 and
occupied the hydrophobic clamp with the methoxyphenyl ring
of their biphenyl linker. The (4aR,8aS)-enantiomer was
observed in the crystal structures of both inhibitors. In the
case of 8, we therefore propose the 100-fold more potent
enantiomer 8b to be (4aR,8aS)-conﬁgured. Compounds 8 and
9 successfully targeted the P-pocket. The glycinamide tail of 8
formed a direct hydrogen bond to Tyr845Q2.36 and three water-
mediated hydrogen bonds to the following residues: (1)
Thr841Q2.33 and Met861S.40; (2) Leu870Q2.46 and Gln874Q.50;
and (3) Gly873Q2.49. Alignment of the crystal structure of 8
with the nonselective inhibitor 1 clearly highlights the
distinctive binding mode of the tail groups (Figure 5).
However, the 4a,5,8,8a-tetrahydrophthalazinone and methoxy-
substituted phenyl rings of 1 and 8 closely aligned in the active
site of TbrPDEB1 and therefore will be competitive inhibitors
of cAMP breakdown. The tail group of 9 was observed in a
slightly diﬀerent conformation, with direct hydrogen bonds
formed to Tyr845Q.2.36 and Glu869Q2.45 and two water-
mediated hydrogen bonds to (1) Thr841Q2.33 and Met861S.40
and (2) Leu870Q2.46 and Gln874Q.50. Average temperature
factors (B factors) indicated greater ﬂexibility in the P-pocket
region of TbrPDEB1 compared to the rest of the protein. The
observed electron density for the glycinamide tail of these
inhibitors was somewhat weaker than that for the rest of the
ligand, indicative of greater ligand ﬂexibility in the P-pocket
region. Both ﬁndings have been supported by observations
from molecular dynamics (MD) simulations (data not shown).
Attempts to elongate the glycinamide tail of compound 8
with a 2-hydroxyethyl substituent to further probe the P-pocket
led to compound 16. In the 2.1 Å crystal structure of 16 with
TbrPDEB1, the elongated tail was found to penetrate the P-
pocket (Figure 6). The overall binding mode for the single
enantiomer (4aR,8aS)-16 was similar to that observed for
glycinamide analogs 8 and 9. This modiﬁcation was not
accompanied by an increase in TbrPDEB1 activity.
The main residues lining the P-pocket in TbrPDEB1 are
Ala837Q1.30, Thr841Q2.33, Tyr845Q2.36, Asn867Q2.43, Met868Q2.44,
Glu869Q2.45, and Leu870Q2.46, with residues from the adjacent
M-loop potentially playing a minor role. The character of these
residues and the ﬂexibility of the P-pocket prompted us to
direct chemistry eﬀorts toward a series of aliphatic heterocyclic
tail substituents in order to introduce rigidity into the tail
region to further interrogate the P-pocket (Table 3).
Compound 18 and its N-methylated counterpart 19 were
designed as constrained analogs of 8. However, cyclization of
the glycinamide led to a loss of selectivity for TbrPDEB1 over
hPDE4B1 and reduced potency. As seen for the noncyclized
analogs, N-methylation (19) led to a further reduction in
potency. The pyrrolidin-3-one analog (20) was comparable to
18 and 19 in TbrPDEB1 potency but was ∼3-fold selective
over hPDE4B1, indicating that a nitrogen in this ring is not
necessary for selectivity. Going from a pyrrolidin-3-one to a
(R)-pyrrolidin-3-ol substituent (21) increased the TbrPDEB1
selectivity to 9-fold and led to a more potent TbrPDEB1
inhibitor. Interestingly, its isopropyl-substituted counterpart
(22) was even less potent at hPDE4B1 and displayed a 15-fold
selectivity for TbrPDEB1. Finally, we explored two (R)-
pyrrolidine-2-carboxamide analogs, 23 and 24, and both were
more than 10-fold selective for TbrPDEB1, but overall less
potent.
Figure 4. TbrPDEB1 crystal structures of selective inhibitors. (a) TbrPDEB1−8, including |Fo − Fc|αcalc electron density map contoured at 2.5σ; (b)
TbrPDEB1−9.
Figure 5. Alignment of the TbrPDEB1 crystal structures of 1 (cyan)
and 8 (yellow). Coordinates of Gln874Q.50, P-pocket residues, and
metal cations were derived from TbrPDEB1−8 and are shown for
clarity.
Figure 6. X-ray crystal structure of TbrPDEB1−16.
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In order to investigate how these heterocycles interact with
the P-pocket in TbrPDEB1, we determined the crystal structure
of 22 (Figure 7) bound to TbrPDEB1 at a resolution of 1.8 Å.
Only the (4aS,8aR)-enantiomer was observed in the crystal
structure. The (R)-3-hydroxypyrrolidine tail group targeted the
P-pocket through direct hydrogen bonds to the backbone
carbonyl of Met861S.40 and to the side chain of Asn867Q2.43. A
water molecule was also observed making a polar interaction
with the hydroxyl substituent. Furthermore, the carbonyl
oxygen of the tail was within hydrogen bonding distance of a
water molecule coordinated by Glu869Q2.45, Lys872Q2.48, and
Gly873Q2.49. It should be noted that in this crystal structure, 22
was only present at the chain with a symmetry-related molecule
close to the ligand binding site. However, the pose of 22 was in
line with the overall binding modes observed for the other
TbrPDEB1 inhibitors in this series.
We have previously shown that inhibition of TbrPDEB1 and
TbrPDEB2 by 1 in T. b. brucei leads to a rapid and dose-
dependent increase in intracellular cAMP levels.10,11,22
Incubation of bloodstream form trypanosomes with 8 increased
intracellular cAMP levels in these parasites in a dose-dependent
fashion (Figure 8). Compound 8 showed a small but signiﬁcant
eﬀect at 100 nM (P < 0.05) and a strong increase of cAMP level
at 10 μM (P < 0.001), a concentration that was equally eﬀective
Table 3. SAR of Aliphatic Heterocycles in the P-Pocketa
apKi values are averages (n ≥ 2, with SD less than ±0.3 for all). bCompounds are racemic mixtures of cis-isomers. cSelectivity is calculated as
hPDE4B1 (Ki)/TbrPDEB1 (Ki).
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as 0.3 μM of 1, used as positive control. The eﬀect on the
intracellular cAMP levels of the antitrypanosomal compound
pentamidine, used as a negative control, was not statistically
diﬀerent from untreated parasites.
Having identiﬁed and characterized 8 as a selective
TbrPDEB1 inhibitor, we initiated further phenotypic proﬁling.
It has been reported that inhibition of cAMP metabolism
causes severe cellular defects in T. brucei, particularly the ability
of the cells to complete cell division, as cytokinesis and
abscission are impaired, while nuclear and kinetoplast division
remain apparently unaﬀected.6,8,10 This leads to misshapen and
nonviable cells with multiple nuclei and kinetoplasts.
Incubation with 8 at a concentration of 10 μM had the same
eﬀect: after incubation of healthy trypanosomes (Figure 9a) for
6 h (roughly equivalent to one doubling time under standard
culture conditions) with 10 μM compound 8, cells could be
seen to have undergone at least one round of nuclear and
kinetoplast division but without completing cell division into
daughter cells (Figure 9b), indicating a defect in cytokinesis. At
12 h, this had resulted in rounded cells with multiple ﬂagella,
some of them detached, and at least 4 nuclei (Figure 9c). At 24
h, only a few live cells could be detected, all of which were
severely misshapen (Figure 9d). These results were consistent
with the observed antitrypanosomal activity of 8 (IC50 = 5.5 ±
3.3 μM). The isopropyl analog 9 displayed similar anti-T. brucei
eﬀects (IC50 = 6.7 ± 1.6 μM) in the same cytokinesis assay.
While exhibiting a potency in the sub-micromolar range against
TbrPDEB1, the observed lower antitrypanosomal activity might
be due to reduced cell penetration properties. At these
concentrations, oﬀ-target eﬀects can also not be ruled out.
However, the cytotoxic eﬀects of 8 and 9 against human MRC-
5 cells were comparable for both compounds (CC50 = 36 and
35 μM, respectively) and clearly lower than the antiparasitic
eﬀects. Yet, because of the relatively narrow selectivity, these
compounds do not meet the published criteria of drug
candidates for the treatment of human African trypanosomia-
sis,23 and their trypanocidal activity, in particular, requires
further phenotypic optimization.
■ CHEMISTRY
The chemical synthesis of compounds 3−6 and intermediate
28 proceeded as shown in Scheme 1. The key 4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one building block (25)24−26 was
N-alkylated with the appropriate alkyl halides, and a Suzuki
cross-coupling reaction aﬀorded the biaryl systems.
Compounds 7−10, 14−18, 21−24, and 29 were prepared
using carbodiimide-mediated amide coupling methods using 4
or 28 as starting material (Scheme 2). Amide coupling was
performed without the addition of DIPEA in the synthesis of
15, 21, 23, and 24 or without Et3N in the case of analog 22.
To enable access to the enantiomers of 8, racemic 4 was
separated into its enantiomers 4a and 4b using preparative
chiral HPLC. Each of the enantiomers of 4 was reacted with 2-
aminoacetamide, as depicted in Scheme 2. Enantiomer 8a was
obtained with 99.6% ee, while its optical isomer 8b was
Figure 7. X-ray crystal structure of TbrPDEB1−22.
Figure 8. Intracellular cAMP levels in T. brucei after treatment with 8
(NPD-008), with 0.3 μM of compound 1 (NPD-001) used as a
positive control, and pentamidine as a negative control.
Figure 9. Fluorescence microscopy of wild-type T. brucei incubated
with 8 (10 μM) for the following periods: (a) 0 h (control); (b) 6 h;
(c) 12 h; (d) 24 h. Left panels are brightﬁeld images, middle panels are
ﬂuorescence images after DAPI staining, and the right-hand panels are
the merged images. Scale bars, 5 μm.
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obtained with 96.6% ee. The X-ray crystal structures indicate
that TbrPDEB1 exhibits chiral discrimination, allowing the
tentative assignment of the absolute conﬁguration of (4aR,8aS)
to 8b, as this enantiomer possesses a 100-fold higher potency
than 8a.
The synthesis of 11−13 is outlined in Scheme 3. Methyl
ester 29 was treated with aqueous base to give intermediate 30,
and subsequent carbodiimide-mediated amide coupling yielded
11−13. Compound 13 was prepared without the addition of
DIPEA.
Scheme 4 depicts the synthesis of 19 and 20. Analog 19 was
prepared by the N-alkylation of 18 using iodomethane. Finally,
compound 20 was attained by the oxidation of 21 using Dess−
Martin periodinane.
■ CONCLUSION
In summary, we have identiﬁed the ﬁrst series of selective
TbrPDEB1 inhibitors reported to date and explain their
speciﬁcity for TbrPDEB1 over hPDE4 isoforms on the basis
of the cocrystal structures obtained. We have also explained
why previously reported inhibitors failed to show any
selectivity. Our novel trypanocidal TbrPDEB1 inhibitors
feature a tail group containing a rigid biphenyl system with
polar substituents for targeting the P-pocket. Structural data
currently available on the PDEs of L. major and T. cruzi indicate
the presence of similar P-pockets in those enzymes,18,19 while
human PDEs do not have such a pocket.21 Therefore, this work
identiﬁes important possibilities for the development of
parasite-selective PDE inhibitors for a variety of neglected
tropical diseases.
■ EXPERIMENTAL SECTION
Chemistry. All reagents and solvents were obtained from
commercial suppliers and were used as received. All reactions were
magnetically stirred and carried out under an inert atmosphere.
Reaction progress was monitored using thin-layer chromatography
(TLC) and LC-MS analysis. Silica gel column chromatography was
carried out manually or with automatic puriﬁcation systems using the
indicated eluent. Nuclear magnetic resonance (NMR) spectra were
recorded on Bruker Avance 500 (500 MHz for 1H and 126 MHz for
13C) or Bruker Avance 600 (600 MHz for 1H and 151 MHz for 13C)
instruments equipped with a Bruker CryoPlatform, or a Bruker
DMX300 (300 MHz). Chemical shifts (δ in ppm) and coupling
constants (J in Hz) are reported with residual solvent as internal
standard (δ 1H NMR, CDCl3 7.26, DMSO-d6 2.50; δ
13C NMR,
CDCl3 77.16, DMSO-d6 39.52). Various compounds exhibited
rotamers leading to more complicated 1H NMR spectra and less
accurate integrations. LC-MS analysis was performed on a Shimadzu
LC-20AD liquid chromatograph pump system, equipped with an
Xbridge (C18) 5 μm column (50 mm, 4.6 mm), connected to a
Shimadzu SPD-M20A diode array detector, and MS detection using a
Shimadzu LC-MS-2010EV mass spectrometer. The LC-MS conditions
were as follows: solvent B (acetonitrile with 0.1% formic acid) and
solvent A (water with 0.1% formic acid), ﬂow rate of 1.0 mL/min, start
5% B, linear gradient to 90% B in 4.5 min, then 1.5 min at 90% B, then
linear gradient to 5% B in 0.5 min, then 1.5 min at 5% B; total run time
of 8 min. Analytical chiral HPLC was performed with a Chiralpak AD-
H column (250 mm × 4.6 mm, 5 μm) with the following conditions:
ﬂow, 1 mL/min; column temperature, 35 °C; detection, 270 nm;
eluent, heptane/isopropanol 9:1; runtime, 30 min. Exact mass
measurement (HRMS) was performed on a Bruker micrOTOF-Q
instrument with electrospray ionization (ESI) in positive ion mode
Scheme 1a
aReagents and conditions: (a) alkyl halide, NaH, DMF, RT, 4 h, 65−85%; (b) arylboronic acid, Pd(dppf)Cl2·CH2Cl2, Na2CO3, DME, H2O, 100 °C,
16 h, 48−81%.
Scheme 2a
aReagents and conditions: (a) amine, EDC·HCl, HOAt, DIPEA,
CH2Cl2, RT, 3 h, 38−88% (compounds 7, 10, 14, 15, 17, 18, 21, 23,
24, and 29), or amine, EDC·HCl, HOBt hydrate, Et3N, CH2Cl2, RT,
18 h, 54−65% (compounds 8, 9, 16, and 22), or separation of the
enantiomers of 4 by preparative chiral HPLC, then 4a or 4b, 2-
aminoacetamide·HCl, EDC·HCl, HOAt, DIPEA, CH2Cl2, RT, 24 h,
50−55% (8a, 8b).
Scheme 3a
aReagents and conditions: (a) NaOH, EtOH, RT, 2 h, 89%; (b) amine, EDC·HCl, HOAt, DIPEA, CH2Cl2, RT, 36 h, 29−54%.
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and a capillary potential of 4500 V. Systematic names for molecules
were generated with ChemBioDraw Ultra 14.0.0.117 (PerkinElmer,
Inc.). The reported yields refer to isolated pure products; yields were
not optimized. The purity, reported as the peak area % at 254 nm, of
all ﬁnal compounds was ≥95% based on LC-MS.
Synthetic Procedures. Building block 25,24−26 NPD-001 (1),11
and NPD-340 (2)12 were prepared as described elsewhere. All other
compounds were prepared as described below.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-3-carboxylic Acid (3,
NPD-740).
Prepared from 27 (0.5 g, 1.2 mmol) and 3-boronobenzoic acid (0.25 g,
1.5 mmol) as described for 28. The title compound was obtained in
65% yield. 1H NMR (500 MHz, DMSO-d6) δ 13.09 (s, 1H), 8.05 (s,
1H), 7.92 (d, J = 7.7 Hz, 1H), 7.88 (dd, J = 8.7, 2.3 Hz, 1H), 7.80−
7.71 (m, 2H), 7.56 (t, J = 7.7 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 5.73−
5.56 (m, 2H), 4.74−4.62 (m, 1H), 3.83 (s, 3H), 3.53−3.44 (m, 1H),
2.79 (t, J = 6.1 Hz, 1H), 2.76−2.67 (m, 1H), 2.21−2.05 (m, 2H),
1.96−1.63 (m, 7H), 1.62−1.36 (m, 6H). 13C NMR (126 MHz,
DMSO-d6) δ 167.8, 166.0, 157.7, 154.0, 138.4, 134.1, 131.3, 130.5,
129.5, 128.9, 128.5, 128.3, 128.0, 127.6, 126.4, 124.5, 112.5, 56.3, 55.3,
34.2, 33.3, 33.0, 30.3, 28.7, 28.7, 24.9, 24.8, 23.0, 22.4. LC-MS (ESI):
tR = 5.44 min, area >98%, m/z 473 [M + H]
+. HRMS (ESI) m/z: [M
+ H]+ calcd for C29H33N2O4 473.2435, found 473.2414.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carboxylic Acid (4,
NPD-733).
Prepared from 27 (1.00 g, 2.32 mmol) and 4-boronobenzoic acid
(0.66 g, 4.0 mmol) as described for 28. The title compound was
obtained in 66% yield. 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 8.5
Hz, 2H), 7.84 (dd, J = 8.7, 2.4 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.66
(d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.7 Hz, 1H), 5.85−5.61 (m, 2H),
4.88−4.74 (m, 1H), 3.88 (s, 3H), 3.38−3.27 (m, 1H), 3.09−2.95 (m,
1H), 2.76 (t, J = 5.9 Hz, 1H), 2.27−2.14 (m, 3H), 2.12−1.96 (m, 2H),
1.96−1.85 (m, 1H), 1.85−1.70 (m, 4H), 1.69−1.43 (m, 5H), 1.34−
1.18 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 177.1, 166.0, 157.6,
153.5, 143.8, 130.0, 129.7, 129.7, 128.3, 128.1, 128.0, 127.2, 126.1,
123.9, 111.3, 56.3, 55.8, 34.7, 33.2, 33.0, 31.9, 29.0, 28.4, 28.4, 25.1,
25.0, 22.7, 22.4. LC-MS (ESI): tR = 5.41 min, area: 98%, m/z 473 [M
+ H]+. HRMS (ESI) m/z: [M + H]+ calcd for C29H33N2O4 473.2435,
found 473.2432.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carboxamide (5, NPD-
584).
Prepared from 27 (200 mg, 0.464 mmol) and (4-carbamoylphenyl)-
boronic acid (116 mg, 0.703 mmol) as described for 28. The title
compound was isolated in 48% yield. 1H NMR (500 MHz, CDCl3) δ
7.90 (d, J = 8.3 Hz, 2H), 7.84 (dd, J = 8.7, 2.3 Hz, 1H), 7.78 (d, J = 2.4
Hz, 1H), 7.65 (d, J = 8.3 Hz, 2H), 7.06 (d, J = 8.7 Hz, 1H), 6.13 (s,
1H), 5.84−5.66 (m, 2H), 5.62 (s, 1H), 4.87−4.77 (m, 1H), 3.89 (s,
3H), 3.38−3.27 (m, 1H), 3.06−2.97 (m, 1H), 2.76 (t, J = 6.0 Hz, 1H),
2.26−1.70 (m, 8H), 1.69−1.60 (m, 4H), 1.57−1.42 (m, 3H). 13C
NMR (126 MHz, CDCl3) δ 168.9, 165.9, 157.6, 153.3, 142.0, 131.9,
129.8, 129.7, 128.2, 128.1, 127.2, 127.1, 126.1, 123.9, 111.3, 56.2, 55.8,
34.7, 33.2, 33.0, 31.1, 28.43, 28.36, 25.04, 24.98, 23.1, 22.4. LC-MS
(ESI): tR = 5.34 min, area: 96%, m/z 472 [M + H]
+. HRMS (ESI) m/
z: [M + H]+ calcd for C29H34N3O3 472.2595, found 472.2593.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carbonitrile (6, NPD-
744).
Scheme 4a
aReagents and conditions: (a) iodomethane, NaH, DMF, RT, 1.5 h, 54%; (b) Dess−Martin periodinane, CH2Cl2, RT, 4 h, 58%.
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Prepared from 27 (1.0 g, 2.3 mmol) and 4-cyanophenylboronic acid
(0.51 g, 3.5 mmol) as described for 28. The title compound was
obtained in 81% yield. 1H NMR (500 MHz, DMSO-d6) δ 7.92 (dd, J =
8.7, 2.3 Hz, 1H), 7.89 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 2.3 Hz, 1H),
7.71 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.8 Hz, 1H), 5.73−5.55 (m, 2H),
4.72−4.62 (m, 1H), 3.83 (s, 3H), 3.54−3.44 (m, 1H), 2.80−2.68 (m,
2H), 2.20−2.07 (m, 2H), 1.96−1.61 (m, 7H), 1.61−1.35 (m, 6H). 13C
NMR (126 MHz, DMSO-d6) δ 170.7, 162.4, 158.6, 147.8, 137.2,
135.5, 133.3, 133.1, 132.9, 132.9, 131.1, 129.2, 124.1, 117.4, 115.0,
61.1, 60.2, 39.0, 38.0, 37.8, 35.0, 33.3, 33.3, 29.7, 29.6, 27.7, 27.2. LC-
MS (ESI): tR = 5.93 min, area: >98%, m/z 454 [M + H]
+. HRMS
(ESI) m/z: [M + H]+ calcd for C29H32N3O2 454.2489, found
454.2477.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-N-(2-methoxyethyl)-[1,1′-biphenyl]-4-
carboxamide (7, NPD-734).
EDC·HCl (49 mg, 0.26 mmol) was added to a solution of 4 (0.10 g,
0.21 mmol), HOAt (29 mg, 0.21 mmol), 2-methoxyethanamine (0.024
g, 0.32 mmol), and DIPEA (0.11 mL, 0.64 mmol) in CH2Cl2 (5 mL).
The mixture was stirred at RT for 3 h, diluted with CH2Cl2 (100 mL),
and washed with water (2 × 50 mL) and brine (50 mL). The organic
phase was dried over Na2SO4, ﬁltered, concentrated, and puriﬁed using
a reverse phase C18-silica gel column eluting with water/MeCN +
0.1% HCOOH (gradient, 95:5 to 5:95), to aﬀord 7 in 79% yield. 1H
NMR (500 MHz, DMSO-d6) δ 8.57 (t, J = 5.1 Hz, 1H), 7.90 (d, J =
8.0 Hz, 2H), 7.87 (dd, J = 8.7, 2.3 Hz, 1H), 7.76 (d, J = 2.3 Hz, 1H),
7.58 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 8.7 Hz, 1H), 5.74−5.55 (m, 2H),
4.74−4.59 (m, 1H), 3.82 (s, 3H), 3.54−3.40 (m, 5H), 3.28 (s, 3H),
2.83−2.66 (m, 2H), 2.22−2.06 (m, 2H), 1.96−1.62 (m, 7H), 1.62−
1.34 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 165.0, 164.6, 156.3,
152.5, 139.5, 132.0, 128.2, 126.8, 126.5, 126.2, 126.0, 124.9, 123.1,
111.0, 69.5, 57.0, 54.9, 54.0, 38.0, 32.8, 31.9, 31.6, 28.9, 27.2, 27.2,
23.5, 23.5, 21.6, 21.0. LC-MS (ESI): tR = 5.30 min, area: >98%, m/z
530 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd for C32H40N3O4
530.3013, found 530.3005.
N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-[1,1′-bi-
phenyl]-4-carboxamide (8, NPD-008).
EDC·HCl (183 mg, 0.952 mmol) was added to a solution of 4 (300
mg, 0.635 mmol), HOBt hydrate (97 mg, 0.63 mmol), 2-amino-
acetamide·HCl (105 mg, 0.952 mmol), and Et3N (0.265 mL, 1.90
mmol) in CH2Cl2 (6 mL). The reaction mixture was stirred at RT for
18 h. EtOAc (100 mL) was added, and the resulting solution was
washed with water (2 × 50 mL) and brine (50 mL). The organic phase
was dried over Na2SO4, ﬁltered and concentrated to obtain the crude
product as a light brown oil. The crude oil was puriﬁed on a silica gel
column eluting with CH2Cl2/MeOH (gradient, 100:0 to 95:5), to give
8 as a white solid in 65% yield. 1H NMR (500 MHz, CDCl3) δ 7.91
(d, J = 8.0 Hz, 2H), 7.81 (dd, J = 8.7, 2.3 Hz, 1H), 7.75 (d, J = 2.4 Hz,
1H), 7.62 (d, J = 8.1 Hz, 2H), 7.29−7.24 (m, 1H), 7.03 (d, J = 8.7 Hz,
1H), 6.54 (s, 1H), 5.82−5.61 (m, 3H), 4.85−4.74 (m, 1H), 4.23 (d, J
= 4.7 Hz, 2H), 3.85 (s, 3H), 3.35−3.27 (m, 1H), 3.04−2.94 (m, 1H),
2.73 (t, J = 6.0 Hz, 1H), 2.24−2.12 (m, 2H), 2.10−1.94 (m, 2H),
1.93−1.83 (m, 1H), 1.82−1.68 (m, 4H), 1.67−1.42 (m, 6H). 13C
NMR (126 MHz, CDCl3) δ 171.2, 167.6, 165.9, 157.6, 153.4, 141.9,
132.0, 129.8, 129.7, 128.2, 128.1, 127.1, 127.0, 126.1, 123.9, 111.3,
56.3, 55.8, 43.3, 34.7, 33.2, 33.0, 31.9, 31.1, 28.43, 28.36, 25.1, 25.0,
23.1, 22.4. LC-MS (ESI): tR = 4.69 min, area: >98%, m/z 529 [M +
H]+. HRMS (ESI) m/z: [M + H]+ calcd for C31H37N4O4 529.2809,
found 529.2811.
N-(2-Amino-2-oxoethyl)-5′-((4aS,8aR)-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-[1,1′-bi-
phenyl]-4-carboxamide (8a, NPD-949) and N-(2-Amino-2-
oxoethyl)-5′-((4aR,8aS)-3-cycloheptyl-4-oxo-3,4,4a,5,8,8a-hex-
ahydrophthalazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carboxa-
mide (8b, NPD-1373).
The enantiomers of racemic 4 were separated into 4a (ﬁrst eluting
isomer) and 4b (second eluting isomer) using preparative chiral
chromatography. Analytical chiral HPLC indicated 4a and 4b to have
the same retention times as their respective counterparts in racemic
mixture 4. The title compounds were synthesized from separate
solutions of enantiomerically pure 4 (124 mg, 0.262 mmol) and 2-
aminoacetamide HCl (34.8 mg, 0.315 mmol) as described for 7, and
were isolated in 50−55% yield. Absolute conﬁguration was tentatively
assigned to enantiomer 8b. Compound 8a, Chiralpak AD-H 99.6% ee;
compound 8b, Chiralpak AD-H tR = 19.71 min, 96.9% ee.
N- (2-Amino-2-oxoethyl)-5 ′- (cis-3-isopropyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-[1,1′-bi-
phenyl]-4-carboxamide (9, NPD-039).
Prepared from 28 (300 mg, 0.717 mmol) as described for 8. The title
compound was isolated in 59% yield. 1H NMR (500 MHz, CDCl3) δ
7.91 (d, J = 8.1 Hz, 2H), 7.84 (dd, J = 8.7, 2.3 Hz, 1H), 7.80 (d, J = 2.3
Hz, 1H), 7.65 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 8.7 Hz, 1H), 6.99−6.93
(m, 1H), 5.99 (s, 1H), 5.85−5.64 (m, 2H), 5.48 (s, 1H), 5.06 (hept, J
= 6.8 Hz, 1H), 4.22 (d, J = 4.8 Hz, 2H), 3.89 (s, 3H), 3.39−3.30 (m,
1H), 3.08−2.97 (m, 1H), 2.78 (t, J = 6.0 Hz, 1H), 2.24−2.18 (m, 2H),
2.13−2.00 (m, 1H), 1.34 (d, J = 6.5 Hz, 3H), 1.22 (d, J = 6.7 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 170.7, 167.4, 166.4, 157.6, 153.4,
141.9, 132.0, 129.84, 129.76, 128.2, 128.0, 127.0, 126.9, 126.0, 123.9,
111.2, 55.8, 46.7, 43.3, 34.8, 31.1, 23.2, 22.4, 20.6, 20.2. LC-MS (ESI):
tR = 4.13 min, area: >95%, m/z 475 [M + H]
+. HRMS (ESI) m/z: [M
+ H]+ calcd for C27H31N4O4 475.2340, found 475.2344.
N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-N-meth-
yl-[1,1′-biphenyl]-4-carboxamide (10, NPD-935).
Prepared from 4 (0.20 mg, 0.42 mmol) and 2-(methylamino)-
acetamide·HCl (63 mg, 0.51 mmol) as described for 7. The title
compound was obtained in 38% yield. 1H NMR (500 MHz, DMSO-
d6) δ 7.88 (dd, J = 8.8, 2.3 Hz, 1H), 7.79−7.70 (m, 1H), 7.62−7.38
(m, 5H), 7.26−7.08 (m, 2H), 5.73−5.56 (m, 2H), 4.67 (tt, J = 8.9, 4.7
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Hz, 1H), 4.04 (s, 1H), 3.89−3.78 (m, 4H), 3.49 (dt, J = 11.4, 5.7 Hz,
1H), 3.01−2.91 (m, 3H), 2.81−2.68 (m, 2H), 2.21−2.07 (m, 2H),
1.96−1.65 (m, 7H), 1.60−1.40 (m, 6H). 13C NMR (126 MHz,
DMSO-d6) δ 171.3, 170.3, 166.0, 157.7, 154.0, 139.2, 135.5, 129.6,
129.5, 128.3, 128.0, 127.5, 127.4, 126.9, 126.3, 124.5, 112.5, 56.3, 55.4,
54.0, 39.0, 34.3, 34.3, 33.3, 33.0, 30.3, 28.6, 28.6, 25.0, 24.9, 23.0, 22.4.
LC-MS (ESI): tR = 4.77 min, area: >95%, m/z 543 [M + H]
+. HRMS
(ESI) m/z: [M + H]+ calcd for C32H39N4O4 543.2966, found
543.2969.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-N-(2-(methylamino)-2-oxoethyl)-[1,1′-
biphenyl]-4-carboxamide (11, NPD-936).
EDC·HCl (43 mg, 0.22 mmol) was added to a solution of 30 (0.10 g,
0.19 mmol), HOAt (26 mg, 0.19 mmol), methyl amine·HCl (28 mg,
0.42 mmol), and DIPEA (0.066 mL, 0.38 mmol) in CH2Cl2 (4 mL).
The reaction mixture was stirred at RT for 36 h, CH2Cl2 (100 mL)
was added, and the resulting solution was washed with water (2 × 50
mL) and brine (50 mL). The organic phase was dried over Na2SO4,
ﬁltered, and concentrated. The product was puriﬁed on a silica gel
column eluting with EtOAc, to give 11 as a white solid in 29% yield.
1H NMR (500 MHz, DMSO-d6) δ 8.86 (t, J = 6.0 Hz, 1H), 8.04−7.97
(m, 2H), 7.96−7.88 (m, 2H), 7.83 (d, J = 2.4 Hz, 1H), 7.70−7.63 (m,
2H), 7.28 (d, J = 8.8 Hz, 1H), 5.80−5.63 (m, 2H), 4.73 (td, J = 8.8, 4.5
Hz, 1H), 3.91 (d, J = 5.9 Hz, 2H), 3.89 (s, 3H), 3.55 (dt, J = 11.6, 5.7
Hz, 1H), 2.88−2.75 (m, 2H), 2.67 (d, J = 4.6 Hz, 3H), 2.27−2.13 (m,
2H), 2.02−1.72 (m, 7H), 1.67−1.45 (m, 6H). 13C NMR (126 MHz,
DMSO-d6) δ 169.8, 166.6, 166.0, 157.7, 153.9, 141.1, 133.1, 129.6,
129.6, 128.2, 128.0, 127.7, 127.6, 126.3, 124.5, 112.5, 56.3, 55.4, 43.2,
34.2, 33.3, 33.1, 30.3, 28.6, 28.6, 26.0, 24.9, 24.9, 23.0, 22.4. LC-MS
(ESI): tR = 4.86 min, area: >98%, m/z 543 [M + H]
+. HRMS (ESI)
m/z: [M + H]+ calcd for C32H39N4O4 543.2966, found 543.2963.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-N-(2-(dimethylamino)-2-oxoethyl)-2′-methoxy-
[1,1′-biphenyl]-4-carboxamide (12, NPD-939).
Prepared from 30 (25 mg, 0.048 mmol) and dimethylamine·HCl (8.5
mg, 0.11 mmol) as described for 11. The title compound was obtained
in 54% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.64 (t, J = 5.7 Hz,
1H), 7.99 (d, J = 8.4 Hz, 2H), 7.95 (dd, J = 8.7, 2.3 Hz, 1H), 7.84 (d, J
= 2.3 Hz, 1H), 7.71−7.63 (m, 2H), 7.29 (d, J = 8.8 Hz, 1H), 5.80−
5.64 (m, 2H), 4.74 (tt, J = 8.6, 4.8 Hz, 1H), 4.19 (d, J = 5.6 Hz, 2H),
3.89 (s, 3H), 3.56 (dt, J = 11.5, 5.7 Hz, 1H), 3.09 (s, 3H), 2.92 (s, 3H),
2.88−2.76 (m, 2H), 2.27−2.12 (m, 2H), 2.03−1.73 (m, 7H), 1.67−
1.45 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 168.7, 166.5, 166.0,
157.7, 154.0, 141.1, 133.2, 129.7, 129.6, 128.3, 128.0, 127.6, 127.5,
126.3, 124.5, 112.5, 56.3, 55.4, 41.4, 36.2, 35.6, 34.2, 33.3, 33.1, 30.3,
28.6, 28.6, 25.0, 24.9, 23.0, 22.4. LC-MS (ESI): tR = 5.01 min, area:
>95%, m/z 557 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd for
C33H41N4O4 557.3122, found 557.3114.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-N-(2-(isopropylamino)-2-oxoethyl)-2′-methoxy-
[1,1′-biphenyl]-4-carboxamide (13, NPD-942).
Prepared from 30 (0.10 g, 0.19 mmol) and isopropyl amine (0.034
mL, 0.42 mmol) as described for 11, but excluding DIPEA. The title
compound was obtained in 38% yield. 1H NMR (500 MHz, DMSO-
d6) δ 8.69 (t, J = 5.9 Hz, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.88 (dd, J =
8.7, 2.3 Hz, 1H), 7.82−7.73 (m, 2H), 7.65−7.54 (m, 2H), 7.22 (d, J =
8.8 Hz, 1H), 5.77−5.56 (m, 2H), 4.74−4.62 (m, 1H), 3.91−3.83 (m,
3H), 3.83 (s, 3H), 3.49 (dt, J = 11.6, 5.8 Hz, 1H), 2.81−2.69 (m, 2H),
2.20−2.08 (m, 2H), 1.95−1.65 (m, 7H), 1.61−1.36 (m, 6H), 1.07 (d, J
= 6.6 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 168.2, 166.5, 166.0,
157.7, 154.0, 141.1, 133.2, 129.6, 129.6, 128.2, 128.0, 127.6, 127.6,
126.3, 124.5, 112.5, 56.3, 55.4, 43.0, 40.9, 33.3, 33.1, 30.3, 28.6, 28.6,
24.9, 24.9, 23.0, 22.9, 22.4. LC-MS (ESI): tR = 5.17 min, area: >98%,
m/z 571 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd for
C34H43N4O4 571.3279, found 571.3262.
N-(3-Amino-3-oxopropyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-[1,1′-bi-
phenyl]-4-carboxamide (14, NPD-800).
Prepared from 4 (80 mg, 0.17 mmol) and 3-aminopropanamide·HCl
(42 mg, 0.34 mmol) as described for 7. The title compound was
obtained in 64% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.55 (t, J =
5.6 Hz, 1H), 7.87 (dd, J = 8.7, 2.5 Hz, 3H), 7.76 (d, J = 2.3 Hz, 1H),
7.62−7.54 (m, 2H), 7.43−7.35 (m, 1H), 7.22 (d, J = 8.8 Hz, 1H), 6.86
(s, 1H), 5.73−5.58 (m, 2H), 4.73−4.62 (m, 1H), 3.82 (s, 3H), 3.54−
3.41 (m, 3H), 2.81−2.68 (m, 2H), 2.36 (t, J = 7.2 Hz, 2H), 2.22−2.08
(m, 2H), 1.97−1.63 (m, 8H), 1.63−1.39 (m, 6H). 13C NMR (126
MHz, DMSO-d6) δ 173.0, 166.4, 166.0, 157.7, 154.0, 140.9, 133.6,
129.6, 128.2, 128.0, 127.6, 127.4, 126.3, 124.5, 112.5, 56.3, 55.4, 36.5,
35.5, 34.2, 33.3, 33.1, 30.3, 28.7, 28.6, 28.6, 25.0, 24.9, 23.0, 22.4. LC-
MS (ESI): tR = 4.72 min, area: >95%, m/z 543 [M + H]
+. HRMS
(ESI) m/z: [M + H]+ calcd for C32H39N4O4 543.2966, found
543.2966.
N- (2-Acetamidoethyl)-5 ′ - (cis -3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-[1,1′-bi-
phenyl]-4-carboxamide (15, NPD-801).
Prepared from 4 (80 mg, 0.17 mmol) and N-(2-aminoethyl)acetamide
(35 mg, 0.34 mmol) as described for 7, but excluding DIPEA. The title
compound was obtained in 78% yield. 1H NMR (500 MHz, DMSO-
d6) δ 8.55 (t, J = 5.6 Hz, 1H), 8.00 (t, J = 5.8 Hz, 1H), 7.91−7.84 (m,
3H), 7.76 (d, J = 2.3 Hz, 1H), 7.62−7.55 (m, 2H), 7.22 (d, J = 8.9 Hz,
1H), 5.74−5.56 (m, 2H), 4.67 (tt, J = 8.5, 4.9 Hz, 1H), 3.82 (s, 3H),
3.49 (dt, J = 11.4, 5.7 Hz, 1H), 3.31 (q, J = 6.1 Hz, 2H), 3.21 (q, J =
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6.3 Hz, 2H), 2.81−2.68 (m, 2H), 2.21−2.07 (m, 2H), 1.93−1.66 (m,
11H), 1.60−1.40 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 170.0,
166.5, 166.0, 157.7, 154.0, 141.0, 133.6, 129.6, 129.6, 128.2, 128.0,
127.6, 127.4, 126.3, 124.5, 112.5, 56.3, 55.4, 39.7, 38.7, 34.2, 33.3, 33.1,
30.3, 28.6, 28.6, 25.0, 24.9, 23.1, 23.0, 22.4. LC-MS (ESI): tR = 4.84
min, area: >95%, m/z 557 [M + H]+. HRMS (ESI) m/z: [M + H]+
calcd for C33H41N4O4 557.3122, found 557.3128.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-2′-me-
thoxy-[1,1′-biphenyl]-4-carboxamide (16, NPD-937).
Prepared from 4 (200 mg, 0.423 mmol) and 2-amino-N-(2-
hydroxyethyl)acetamide·HCl (65 mg, 0.42 mmol) as described for 8.
The title compound was obtained in 54% yield. 1H NMR (500 MHz,
CDCl3) δ 7.84 (d, J = 8.1 Hz, 2H), 7.75 (dd, J = 8.7, 2.3 Hz, 1H), 7.69
(d, J = 2.2 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.14 (t, J = 5.2 Hz, 1H),
6.97 (d, J = 8.7 Hz, 1H), 6.77 (t, J = 4.7 Hz, 1H), 5.75−5.56 (m, 2H),
4.79−4.68 (m, 1H), 4.14 (d, J = 4.9 Hz, 2H), 3.79 (s, 3H), 3.70 (t, J =
4.9 Hz, 2H), 3.43 (q, J = 5.2 Hz, 2H), 3.28−3.21 (m, 1H), 2.99−2.88
(m, 1H), 2.67 (t, J = 6.0 Hz, 1H), 2.19−2.05 (m, 2H), 2.04−1.73 (m,
8H), 1.66−1.36 (m, 7H). 13C NMR (126 MHz, CDCl3) δ 169.7,
167.8, 165.9, 157.6, 153.3, 142.1, 131.9, 129.9, 129.7, 128.2, 128.1,
127.1, 127.0, 126.1, 123.9, 111.3, 61.9, 56.2, 55.8, 43.8, 42.5, 34.7, 33.2,
33.0, 31.1, 28.43, 28.37, 25.1, 25.0, 23.1, 22.4. LC-MS (ESI): tR = 4.63
min, area: >98%, m/z 573 [M + H]+. HRMS (ESI) m/z: [M + H]+
calcd for C33H41N4O5 573.3071, found 573.3057.
5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-N-(2-((2-methoxyethyl)amino)-2-ox-
oethyl)-[1,1′-biphenyl]-4-carboxamide (17, NPD-878).
Prepared from 4 (0.15 g, 0.32 mmol) and 2-amino-N-(2-
methoxyethyl)acetamide (50 mg, 0.38 mmol) as described for 7.
The title compound was obtained in 32% yield. 1H NMR (500 MHz,
DMSO-d6) δ 8.77 (t, J = 6.0 Hz, 1H), 8.00 (t, J = 5.7 Hz, 1H), 7.94 (d,
J = 8.4 Hz, 2H), 7.88 (dd, J = 8.7, 2.3 Hz, 1H), 7.78 (d, J = 2.4 Hz,
1H), 7.65−7.55 (m, 2H), 7.22 (d, J = 8.8 Hz, 1H), 5.74−5.57 (m,
2H), 4.73−4.62 (m, 1H), 3.88 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.49
(dt, J = 11.5, 5.7 Hz, 1H), 3.40−3.31 (m, 2H), 3.25 (d, J = 5.0 Hz,
5H), 2.82−2.68 (m, 2H), 2.22−2.07 (m, 2H), 1.97−1.64 (m, 7H),
1.61−1.37 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 169.1, 166.2,
165.6, 157.3, 153.5, 140.7, 132.7, 129.2, 129.2, 127.8, 127.6, 127.2,
125.9, 124.1, 112.0, 70.6, 58.0, 55.9, 55.0, 42.6, 38.4, 33.8, 32.9, 32.6,
29.9, 28.2, 28.2, 24.5, 24.5, 22.6, 22.0. LC-MS (ESI): tR = 4.92 min,
area: >98%, m/z 587 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd
for C34H43N4O5 587.3228, found 587.3220.
cis-2-Cycloheptyl-4-(6-methoxy-4′-(4-oxoimidazolidine-1-
carbonyl)-[1,1′-biphenyl]-3-yl)-4a,5,8,8a-tetrahydrophthala-
zin-1(2H)-one (18, NPD-060).
Prepared from 4 (0.20 g, 0.42 mmol) and imidazolidin-4-one·HCl (70
mg, 0.57 mmol) as described for 7. The title compound was obtained
in 88% yield. Note: less accurate integrations due to rotamers/
diastereomers. 1H NMR (600 MHz, DMSO-d6) δ 8.71 (s, 0.6H), 8.61
(s, 0.4H), 7.90 (dd, J = 8.7, 2.4 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.69
(d, J = 7.9 Hz, 1H), 7.61 (m, 3H), 7.25 (d, J = 8.8 Hz, 1H), 5.73−5.60
(m, 2H), 4.90 (m, 2H), 4.69 (tt, J = 9.0, 4.8 Hz, 1H), 4.08 (s, 0.6H),
3.98 (s, 0.4H), 3.85 (s, 3H), 3.50 (m, 1H), 2.82−2.70 (m, 2H), 2.20−
2.10 (m, 2H), 1.97−1.89 (m, 1H), 1.88−1.68 (m, 6H), 1.62−1.41 (m,
6H). LC-MS (ESI): tR = 4.81 min, area: >95%, m/z 541 [M + H]
+.
HRMS (ESI) m/z: [M + H]+ calcd for C32H37N4O4 541.2809, found
541.2792.
cis-2-Cycloheptyl-4-(6-methoxy-4′-(3-methyl-4-oxoimidazo-
lidine-1-carbonyl)-[1,1′-biphenyl]-3-yl)-4a,5,8,8a-tetrahy-
drophthalazin-1(2H)-one (19, NPD-062).
To an ice-cooled solution of 18 (0.10 g, 0.19 mmol) in DMF (4 mL),
sodium hydride (60% dispersion in mineral oil, 9.3 mg, 0.21 mmol)
was added. The temperature of the mixture was allowed to increase to
RT; after 30 min iodomethane (27 mg, 0.19 mmol, 12 μL) was added.
This mixture was stirred for 1.5 h, diluted with water (25 mL) and
extracted with CH2Cl2 (3 × 45 mL). The combined organic phases
were washed with brine (15 mL), dried over Na2SO4, ﬁltered,
concentrated, and puriﬁed on a silica gel column eluting with CH2Cl2/
MeOH (gradient, 100:0 to 96:4). The product was freeze-dried to
obtain 19 in 54% yield. 1H NMR (500 MHz, DMSO-d6) δ 7.89 (dd, J
= 8.7, 2.2 Hz, 1H), 7.76 (t, J = 2.8 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H),
7.65−7.57 (m, 3H), 7.24 (d, J = 8.7 Hz, 1H), 5.73−5.57 (m, 2H),
4.99−4.90 (m, 2H), 4.68 (tt, J = 8.8, 4.8 Hz, 1H), 4.17 (s, 1H), 4.07 (s,
1H), 3.84 (s, 3H), 3.49 (dt, J = 11.6, 5.8 Hz, 1H), 2.86 (s, 2H), 2.81−
2.69 (m, 3H), 2.21−2.07 (m, 2H), 1.97−1.65 (m, 7H), 1.62−1.38 (m,
6H). 13C NMR (126 MHz, DMSO-d6) δ 168.1, 167.4, 166.0, 157.7,
153.9, 140.4, 133.8, 129.8, 129.7, 129.3, 128.3, 128.0, 127.7, 127.6,
127.4, 126.3, 124.4, 112.5, 64.4, 56.3, 55.4, 50.5, 34.2, 33.2, 33.0, 30.3,
28.6, 28.5, 27.4, 24.9, 24.8, 23.0, 22.4. LC-MS (ESI): tR = 3.85 min,
area: >95%, m/z 555 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd
for C33H39N4O4 555.2966, found 555.2957.
cis-2-Cycloheptyl-4-(6-methoxy-4′-(3-oxopyrrolidine-1-car-
bonyl)-[1,1′-biphenyl]-3-yl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (20, NPD-887).
To a solution of 21 (0.58 g, 1.1 mmol) in CH2Cl2 (3 mL), Dess−
Martin periodinane (0.11 g, 2.7 mmol) was added, and the reaction
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mixture was stirred at RT for 4 h. Water (0.019 mL, 1.1 mmol) was
added, and the mixture was stirred for an additional 30 min. A mixture
of aqueous 10% sodium metabisulﬁte and saturated aqueous sodium
bicarbonate (1:1 ratio, 2 mL total volume) was added, the resulting
mixture was extracted with CH2Cl2 (20 mL) and washed with sodium
bicarbonate (2 × 10 mL). The organic phase was concentrated, and
the product was puriﬁed on a silica gel column eluting with EtOAc/
heptane (gradient, 6:4 to 9:1), to aﬀord 20 as a white solid in 58%
yield. 1H NMR (500 MHz, DMSO-d6) δ 7.95 (dd, J = 8.7, 2.4 Hz,
1H), 7.82 (d, J = 2.3 Hz, 1H), 7.71−7.59 (m, 4H), 7.30 (d, J = 8.8 Hz,
1H), 5.81−5.60 (m, 2H), 4.74 (tt, J = 8.9, 4.8 Hz, 1H), 4.09−3.94 (m,
4H), 3.90 (s, 3H), 3.56 (dt, J = 11.5, 5.8 Hz, 1H), 2.87−2.75 (m, 2H),
2.67 (t, J = 7.8 Hz, 2H), 2.26−2.15 (m, 2H), 2.02−1.73 (m, 7H),
1.66−1.47 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 169.1, 166.0,
157.7, 154.0, 139.9, 129.7, 129.5, 128.3, 128.0, 127.5, 126.3, 124.5,
112.5, 56.3, 55.6, 55.4, 52.7, 46.4, 42.8, 37.9, 36.1, 34.2, 33.3, 33.1,
30.3, 28.6, 28.6, 25.0, 24.9, 23.0, 22.4. LC-MS (ESI): tR = 5.19 min,
area: >95%, m/z 540 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd
for C33H38N3O4 540.2857, found 540.2880.
cis-2-Cycloheptyl-4-(4′-((R)-3-hydroxy-pyrrolidine-1-carbon-
yl)-6-methoxy-[1,1′-biphenyl]-3-yl)-4a,5,8,8a-tetrahydroph-
thalazin-1(2H)-one (21, NPD-746).
Prepared from 4 (0.83 g, 1.8 mmol) and (R)-pyrrolidin-3-ol (0.18 g,
2.1 mmol) as described for 7, but excluding DIPEA. The title
compound was obtained in 75% yield. 1H NMR (500 MHz, DMSO-
d6) δ 7.89 (dd, J = 8.7, 2.3 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.62−
7.55 (m, 4H), 7.24 (d, J = 8.8 Hz, 1H), 5.75−5.57 (m, 2H), 5.05 (d, J
= 3.5 Hz, 0H), 4.96 (d, J = 3.1 Hz, 1H), 4.74−4.63 (m, 1H), 4.35 (s,
1H), 4.26 (s, 1H), 3.84 (s, 3H), 3.68−3.45 (m, 4H), 3.42−3.38 (m,
1H), 3.30−3.25 (m, 1H), 2.83−2.70 (m, 2H), 2.21−2.09 (m, 2H),
1.98−1.65 (m, 9H), 1.63−1.39 (m, 6H). 13C NMR (126 MHz,
DMSO) δ 168.7, 166.0, 157.7, 154.0, 139.6, 136.1, 129.6, 129.5, 128.3,
128.0, 127.5, 127.4, 126.4, 124.5, 112.5, 69.8, 68.5, 57.6, 56.3, 55.4,
54.9, 47.4, 44.6, 34.9, 34.3, 33.3, 33.1, 32.6, 30.3, 28.6, 28.6, 25.0, 24.9,
23.0, 22.4. LC-MS (ESI): tR = 4.91 min, area: >98%, m/z 542 [M +
H]+. HRMS (ESI) m/z: [M + H]+ calcd for C33H40N3O4 542.3013,
found 542.3013.
cis-4-(4′-((R)-3-Hydroxypyrrolidine-1-carbonyl)-6-methoxy-
[1,1′-biphenyl]-3-yl)-2-isopropyl-4a,5,8,8a-tetrahydrophthala-
zin-1(2H)-one (22, NPD-038).
Prepared from 28 (300 mg, 0.717 mmol) and (R)-pyrrolidin-3-ol (62
mg, 0.72 mmol) analogous to the method described for 8 but
excluding Et3N. The title compound was isolated in 64% yield.
1H
NMR (500 MHz, CDCl3) δ 7.81 (dd, J = 8.7, 2.3 Hz, 1H), 7.77 (d, J =
2.4 Hz, 1H), 7.67−7.53 (m, 4H), 7.02 (d, J = 8.7 Hz, 1H), 5.82−5.64
(m, 2H), 5.04 (hept, J = 6.6 Hz, 1H), 4.69−4.41 (m, 1H), 3.86 (s,
3H), 3.88−3.47 (m, 5H), 3.39−3.26 (m, 1H), 3.06−2.93 (m, 1H),
2.75 (t, J = 6.0 Hz, 1H), 2.29−1.96 (m, 5H), 1.32 (d, J = 6.6 Hz, 3H),
1.20 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.9, 166.4,
157.7, 153.5, 139.9, 135.3, 130.1, 129.4, 128.3, 128.0, 127.1, 126.8,
126.0, 124.0, 111.2, 71.0, 69.8, 57.4, 55.8, 55.0, 47.4, 46.7, 34.8, 31.1,
23.2, 22.4, 20.6, 20.2. LC-MS (ESI): tR = 4.31 min, area: >98%, m/z
488 [M + H]+. HRMS (ESI) m/z: [M + H]+ calcd for C29H34N3O4
488.2544, found 488.2534.
(R)-1-(5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahy-
drophthalazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-
pyrrolidine-2-carboxamide (23, NPD-802).
Prepared from 4 (80 mg, 0.17 mmol) and (R)-pyrrolidine-2-
carboxamide (38 mg, 0.34 mmol) as described for 7, but excluding
DIPEA. The title compound was obtained in 78% yield. Note: less
accurate integrations due to rotamers/diastereomers. 1H NMR (500
MHz, DMSO-d6) δ 7.88 (dd, J = 8.8, 2.3 Hz, 1H), 7.76 (d, J = 2.3 Hz,
0.7H), 7.72 (d, J = 2.3 Hz, 0.3H), 7.64 (d, J = 8.1 Hz, 1.7H), 7.57 (d, J
= 8.1 Hz, 1.7H), 7.53 (d, J = 7.9 Hz, 0.6H), 7.46−7.39 (m, 1.6H), 7.23
(d, J = 8.7 Hz, 1H), 7.05 (d, J = 3.2 Hz, 0.3H), 6.98 (s, 0.8H), 5.74−
5.56 (m, 2H), 4.75−4.63 (m, 1H), 4.38 (dd, J = 8.2, 5.6 Hz, 0.8H),
4.25 (d, J = 8.0 Hz, 0.3H), 3.83 (s, 3H), 3.70−3.54 (m, 1.3H), 3.54−
3.44 (m, 1.8H), 2.83−2.68 (m, 2H), 2.27−2.07 (m, 3H), 1.94−1.66
(m, 10H), 1.62−1.37 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ
173.7, 168.3, 165.6, 157.3, 153.6, 139.3, 135.4, 129.2, 129.0, 127.9,
127.6, 127.2, 127.1, 126.5, 125.9, 124.1, 112.1, 60.2, 55.9, 55.0, 49.9,
33.8, 32.9, 32.6, 29.9, 29.7, 28.2, 28.2, 25.1, 24.6, 24.5, 22.6, 22.0. LC-
MS (ESI): tR = 4.89 min, area: >96%, m/z 569 [M + H]
+. HRMS
(ESI) m/z: [M + H]+ calcd for C34H41N4O4 569.3122, found
569.3143.
(R)-1-(5′-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydroph-
thalazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-
pyrrolidine-2-carboxamide (24, NPD-885).
Prepared from 28 (0.10 g, 0.21 mmol) and (R)-pyrrolidine-2-
carboxamide (43 mg, 0.38 mmol) as described for 7, but excluding
DIPEA. The title compound was obtained in 56% yield. 1H NMR (500
MHz, DMSO-d6) δ 7.83 (dd, J = 8.8, 2.4 Hz, 1H), 7.72 (d, J = 2.3 Hz,
1H), 7.58 (d, J = 8.1 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 7.9
Hz, 1H), 7.36 (d, J = 13.1 Hz, 1H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H), 6.92
(s, 1H), 5.67−5.51 (m, 2H), 4.81 (hept, J = 6.7 Hz, 1H), 4.32 (dd, J =
8.3, 5.6 Hz, 1H), 3.77 (d, J = 3.1 Hz, 3H), 3.61−3.49 (m, 1H), 3.43
(dt, J = 11.1, 5.7 Hz, 2H), 2.76−2.63 (m, 2H), 2.18−2.03 (m, 3H),
1.89−1.65 (m, 4H), 1.17 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 6.7 Hz, 3H).
13C NMR (126 MHz, DMSO-d6) δ 174.2, 168.7, 166.5, 157.8, 154.0,
139.7, 135.8, 129.7, 129.4, 128.2, 128.0, 127.7, 127.6, 126.9, 126.3,
124.5, 112.4, 60.6, 56.3, 50.4, 46.2, 34.3, 30.4, 30.2, 25.5, 23.0, 22.4,
20.9, 20.6. LC-MS (ESI): tR = 4.22 min, area: >95%, m/z 515 [M +
H]+. HRMS (ESI) m/z: [M + H]+ calcd for C30H35N4O4 515.2653,
found 515.2652.
cis-4-(3-Bromo-4-methoxyphenyl)-2-isopropyl-4a,5,8,8a-tet-
rahydrophthalazin-1(2H)-one (26). To a solution of 25 (50.0 g,
149 mmol) in DMF (500 mL), NaH (60% dispersion in mineral oil,
14.9 g, 373 mmol) was added at RT. The resulting mixture was stirred
for 30 min, and 2-bromopropane (21.0 mL, 224 mmol) was added.
After stirring the reaction mixture for 4 h, 0.5 M aqueous HCl (1.5 L)
was added, and the resulting suspension was ﬁltered. The residue was
dissolved in a mixture of MeOH and CH2Cl2, dried over Na2SO4,
ﬁltered, and concentrated under reduced pressure. The light brown
solid was triturated with Et2O to give 26 as a white solid in 80% yield.
1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 2.1 Hz, 1H), 7.74 (dd, J =
8.7, 2.2 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 5.85−5.62 (m, 2H), 5.05
(hept, J = 6.7 Hz, 1H), 3.95 (s, 3H), 3.32−3.21 (m, 1H), 3.07−2.95
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(m, 1H), 2.74 (t, J = 6.0 Hz, 1H), 2.28−2.11 (m, 2H), 2.09−1.95 (m,
1H), 1.33 (d, J = 6.6 Hz, 3H), 1.21 (d, J = 6.7 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 166.4, 156.8, 152.3, 130.8, 129.1, 126.2, 126.0, 123.8,
112.2, 111.5, 56.4, 46.8, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2. LC-MS (ESI)
m/z 377/379 [M + H]+.
cis-4-(3-Bromo-4-methoxyphenyl)-2-cycloheptyl-4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one (27). Prepared from building
block 25 and bromocycloheptane as described for 26. The title
compound was prepared in 65% yield. 1H NMR (500 MHz, CDCl3) δ
7.98 (d, J = 2.2 Hz, 1H), 7.71 (dd, J = 8.7, 2.2 Hz, 1H), 6.91 (d, J = 8.6
Hz, 1H), 5.83−5.55 (m, 2H), 4.85−4.71 (m, 1H), 3.92 (s, 3H), 3.30−
3.16 (m, 1H), 3.06−2.89 (m, 1H), 2.69 (t, J = 6.0 Hz, 1H), 2.27−2.06
(m, 2H), 2.06−1.92 (m, 2H), 1.92−1.81 (m, 1H), 1.81−1.67 (m, 4H),
1.67−1.38 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 165.8, 156.8,
152.2, 130.7, 129.1, 126.2, 126.0, 123.8, 112.1, 111.6, 56.4, 56.3, 34.6,
33.2, 33.0, 31.0, 28.34, 28.27, 25.1, 25.0, 23.0, 22.3. LC-MS (ESI) m/z
431/433 [M + H]+.
5′-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthala-
zin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carboxylic Acid (28). To
a degassed solution of 26 (1.00 g, 2.65 mmol) in DME (15 mL), 4-
boronobenzoic acid (0.66 g, 4.0 mmol), Pd(dppf)Cl2·CH2Cl2 (0.13 g,
0.16 mmol), and 2 M aqueous Na2CO3 (5.2 mL) was added. The
mixture was stirred at 100 °C for 16 h, then diluted with saturated
aqueous NH4Cl solution (50 mL) and water (250 mL) and extracted
with CH2Cl2 (150 mL). The organic phase was washed with water
(150 mL) and brine (100 mL), dried over Na2SO4, ﬁltered, and
concentrated. The residue was puriﬁed on a silica gel column eluting
with CH2Cl2/MeOH (gradient, 99:1 to 97:3) to aﬀord 28 in 55%
yield. 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 8.2 Hz, 2H), 7.85
(dd, J = 8.7, 2.3 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.66 (d, J = 8.3 Hz,
2H), 7.05 (d, J = 8.6 Hz, 1H), 5.86−5.63 (m, 2H), 5.06 (hept, J = 6.6
Hz, 1H), 3.89 (s, 3H), 3.40−3.29 (m, 1H), 3.10−2.96 (m, 1H), 2.77
(t, J = 6.0 Hz, 1H), 2.28−2.14 (m, 2H), 2.12−1.99 (m, 1H), 1.33 (d, J
= 6.6 Hz, 3H), 1.21 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3)
δ 171.4, 166.5, 157.7, 153.5, 143.7, 130.1, 129.8, 129.7, 128.3, 128.1,
128.0, 127.2, 126.1, 124.0, 111.3, 55.9, 46.8, 34.8, 31.1, 23.2, 22.4, 20.6,
20.2. LC-MS (ESI) m/z 419 [M + H]+.
Methyl (5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahy-
drophthalazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-
glycinate (29). Prepared from 4 (1.0 g, 2.1 mmol) and glycine methyl
ester·HCl (0.32 g, 2.5 mmol) as described for 7. The title compound
was obtained in 58% yield. 1H NMR (300 MHz, DMSO-d6) δ 9.00 (t,
J = 8.2 Hz, 1H), 7.94 (d, J = 8.5, 2H), 7.90 (dd, J = 8.8, J = 2.3 Hz,
1H) 7.78 (d, J = 2.3 Hz, 1H), 7.63 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.8
Hz, 1H), 5.71−5.60 (m, 2H), 4.73−4.64 (m, 1H), 4.05 (d, J = 5.8 Hz,
2H), 3.83 (s, 3H), 3.67 (s, 3H), 3.51−3.46 (m, 1H), 2.81−2.72 (m,
2H), 2.20−2.11 (m, 2H), 2.00−1.36 (m, 13H).
(5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophtha-
lazin-1-yl)-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)glycine (30).
Aqueous sodium hydroxide (6.2 mL, 25 mmol) was added to a
suspension of 29 (0.84 g, 1.5 mmol) in EtOH (25 mL) and stirred at
RT for 2 h. The reaction mixture was acidiﬁed with HCl (2 M) and
extracted with EtOAc (2 × 30 mL). The combined organic phases
were washed with water, dried over Na2SO4, ﬁltered, and concentrated
to give the title compound as a brown solid in 89% yield. 1H NMR
(300 MHz, DMSO-d6) δ 8.87 (t, J = 5.8 Hz, 1H), 7.95 (d, J = 8.5, 2H),
7.91 (dd, J = 8.9, J = 2.2 Hz, 1H) 7.79 (d, J = 2.3 Hz, 1H), 7.64 (d, J =
8.5 Hz, 2H), 7.26 (d, J = 8.8 Hz, 1H), 5.73−5.61 (m, 2H), 4.74−4.65
(m, 1H), 3.97 (d, J = 5.8 Hz, 2H), 3.85 (s, 3H), 3.55−3.47 (m, 1H),
2.81−2.72 (m, 2H), 2.20−2.11 (m, 2H), 2.00−1.36 (m, 13H). LC-MS
(ESI): tR = 4.93 min, m/z 530 [M + H]
+
Interference Compounds. All ﬁnal compounds have been
examined for the presence of substructures classiﬁed as Pan Assay
Interference Compounds (PAINS) using a KNIME workﬂow.27
Phosphodiesterase Activity Assay. To determine the eﬀect of
test compounds on the enzymatic activity of full length TbrPDEB1
(Km = 7.97 ± 2.32 μM) and full length recombinant hPDE4B1 (Km =
2.0 ± 0.7 μM), the standard scintillation proximity assay (SPA) was
used, as reported previously.10,12 In this assay, the cAMP substrate
concentration was 0.5 μM, and the enzyme concentration was adjusted
so that <20% of substrate was consumed. The Ki values are
represented as the mean of at least two independent experiments
with the associated standard deviation (SD) as indicated.
Gene Constructs for Structural Studies. TbrPDEB1 Catalytic
Domain. A gene segment coding for TbrPDEB1 catalytic domain
residues 565−918 (Uniprot entry Q8WQX9) was PCR ampliﬁed with
ﬂanking NdeI and EcoRI restriction sites and cloned into a pET28a(+)
expression vector (Novagen) previously digested with the same set of
restriction enzymes. An N-terminal, thrombin cleavable 6×His tag was
kept in-frame with the gene to facilitate subsequent puriﬁcation of the
expressed protein by metal aﬃnity chromatography. The resultant
recombinant vector was named pET28a(+)-TbrPDEB1_CD.
hPDE4B Regulatory Domain (UCR2 + Catalytic Domain). Coding
sequence for hPDE4B UCR2 and catalytic domain residues 241−659
(Uniprot entry Q07343) was synthesized and cloned into a pMA
vector (GeneArt, Invitrogen, Life Technologies). This vector was then
used as a PCR template for subcloning of the gene segment into a
pFastBacHTA insect cell expression vector (Invitrogen, Life
Technologies) with a C-terminal 6×His puriﬁcation tag.
hPDE4D2 Catalytic Domain. A gene segment coding for residues
381−740 of hPDE4D2 (Uniprot entry Q08499) was PCR ampliﬁed
using a forward primer including an NdeI restriction site and a reverse
primer including a XhoI restriction site. The PCR product was cloned
into a pET15b E. coli expression vector (Novagen) previously digested
with the same set of enzymes. The primer design was such to keep an
N-terminal 6×His tag from the vector in frame with the target gene.
The resultant recombinant vector was named pET15b-hPDE4D_CD.
Protein Expression and Puriﬁcation for Structural Studies.
TbrPDEB1 Catalytic Domain. Escherichia coli BL21 (DE3) cells were
transformed with pET28a(+)-TbrPDEB1_CD and allowed to grow in
2 L of 2×YT medium at 37 °C until the optical density at 600 nm
reached 0.6−0.8. At this stage, the culture was cooled down, induced
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and further
grown overnight at 16 °C. Cells were collected by centrifugation,
resuspended in a buﬀer containing 20 mM Tris-HCl, pH 7.5, 200 mM
NaCl, 10 mM imidazole, 5% glycerol, 2 mM β-mercaptoethanol
(BME), and protease inhibitor cocktail tablet (Roche), and lysed by
passing through a cell disruptor (20 kpsi/pass). Cleared cell lysate was
loaded onto a 5 mL HisTrap HP nickel aﬃnity column (GE
Healthcare Biosciences) and bound protein was eluted with a linear
gradient of 0−1 M imidazole. Fractions containing the target protein,
as assessed by SDS gel electrophoresis, were pooled and desalted to
remove imidazole. Removal of N-terminal 6×His tag was performed
by overnight incubation at 4 °C of the sample with human thrombin
(Abcam) at 5 NIH units/mL of the pooled sample followed by a
second nickel aﬃnity puriﬁcation step to remove any remaining tagged
fraction. The protein was then dialyzed against ion exchange buﬀer (20
mM Tris-HCl, pH 7.5, 100 mM NaCl, 5% glycerol, 2 mM BME),
loaded onto a HiTrap Q HP column (GE Healthcare Biosciences),
and eluted with a linear gradient of 0−1 M NaCl. A ﬁnal size exclusion
chromatography step was performed on the collected sample using a
Superdex 200 increase 10/300 GL column (GE Healthcare
Biosciences) pre-equilibrated with 20 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 5% glycerol, and 2 mM BME after which the protein was
concentrated using Amicon Ultra concentrators (Millipore) to 7 mg/
mL and stored at −80 °C prior to use. For crystallization trials, NaCl
was removed from the buﬀer while keeping other components intact.
hPDE4B Regulatory Domain (UCR2 + Catalytic Domain).
hPDE4B regulatory domain expression and puriﬁcation was performed
according to the method described.28 Recombinant baculovirus
generation, insect cell (Sf21) culture, and infection were carried out
following manufacturer’s instructions (Bac-to-Bac expression system;
Invitrogen, Life technologies). Infected cells were grown for 48 h at 28
°C and harvested by centrifugation at 500g for 15 min. Lysis was
performed by resuspending the cells in a hypotonic buﬀer of 10 mM
HEPES, pH 7.5, 50 mM NaCl, and 1 mM tris(2-carboxyethyl)
phosphine (TCEP) followed by centrifugation to remove cell debris.
The obtained cleared lysate was loaded onto a 5 mL HisTrap HP
nickel aﬃnity column (GE Healthcare Biosciences) pre-equilibrated
with 100 mM HEPES, pH 7.5, 150 mM NaCl, 50 mM arginine, 10
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mM imidazole, and 1 mM TCEP and eluted with a linear gradient of
0−1 M imidazole. Eluted protein was then dialyzed against ion-
exchange buﬀer (100 mM HEPES, 50 mM NaCl, 1 mM dithiothreitol
(DTT)) and loaded onto a HiTrap Q HP ion exchange column (GE
Healthcare Biosciences). A linear gradient elution of 20−250 mM
NaCl was performed followed by dialysis of the collected sample into
size exclusion buﬀer (10 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM
DTT). Protein was then passed through a Superdex 200 increase 10/
300 GL size exclusion column (GE Healthcare Biosciences). The
collected sample was concentrated to 10 mg/mL and stored at −80 °C
prior to use in crystallization.
hPDE4D2 Catalytic Domain. BL21 (DE3) Codon Plus cells were
transformed with pET15b-hPDE4D_CD and allowed to grow in 1 L
of 2×YT medium at 37 °C until the optical density at 600 nm reached
0.6−0.8. At this stage, culture temperature was lowered, and
expression was induced by addition of 0.5 mM IPTG followed by
further overnight growth at 22 °C. The same cell disruption and
protein puriﬁcation procedures were followed as performed in the case
of TbrPDEB1 catalytic domain protein with the following changes in
the buﬀers used: cell resuspension and nickel aﬃnity chromatography
buﬀer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 5 mM BME, 20 mM
imidazole), ion exchange chromatography buﬀer (50 mM Tris-HCl,
pH 8, 50 mM NaCl, 5 mM DTT), and size exclusion chromatography
buﬀer (50 mM Bis-tris, pH 6.8, 100 mM NaCl, 5 mM DTT). Puriﬁed
protein was concentrated to 9 mg/mL and stored at −80 °C prior to
use in crystallization.
Protein Crystallization, Ligand Soaking and Data Collection.
All crystallization trials were performed by vapor diﬀusion hanging
drop technique, typically with 500 μL reservoir volume and 2 μL
droplets with a protein to crystallization solution ratio of 1:1. Crystals
of the TbrPDEB1 catalytic domain were grown in 20% PEG 3350, 400
mM sodium formate, 300 mM guanidine, and 100 mM MES, pH 6.5,
at 4 °C. Soaking of these crystals with various compounds was
performed maintaining a ﬁnal compound concentration of 5−15 mM
and for varying duration of overnight to 48 h. Soaked crystals were
then brieﬂy dipped in growth solution supplemented with 20% (v/v)
glycerol or ethylene glycol and were mounted using CryoLoop
(Hampton Research) or LithoLoops (Molecular Dimensions) and
vitriﬁed in liquid nitrogen for data collection. In the case of hPDE4D2,
thick plate-like crystals appeared within 5−6 days in a condition
containing 24% PEG 3350, 30% ethylene glycol, and 100 mM HEPES,
pH 7.5, at 19 °C. For hPDE4B, a condition containing 20% PEG 400,
50 mM calcium acetate, and 100 mM sodium acetate, pH 4.6, resulted
in well-diﬀracting crystals. Compound soaking and crystal harvesting
were performed in the same way as for TbrPDEB1 crystals except that
in case of hPDE4D2 no cryopreservative was added prior to
vitriﬁcation. X-ray diﬀraction data sets were collected at Diamond
Light Source (DLS; Didcot, Oxfordshire, UK) beamlines I03 and I04
at 100 K. The data sets were processed by xia229 or autoPROC,30
which incorporates XDS31 and AIMLESS,32 or were integrated using
iMOSFLM33 and reduced using POINTLESS, SCALA, and
TRUNCATE,34 all of which are part of CCP4.35
X-ray Crystal Structure Determination, Reﬁnement, and
Analysis. The crystal structure of TbrPDEB1 bound to NPD-008 (8)
was solved by molecular replacement (MR) using PHASER,36 taking
the apo structure (PDB code 4I15) as search model. Reﬂections for
calculating Rfree were selected randomly, and the same set was used in
all other ligand-bound TbrPDEB1 data sets except for NPD-038 (22)
where the crystal was nonisomorphous. All isomorphous crystal forms
were solved by Fourier synthesis using the partially reﬁned, ligand-free
8 model, whereas MR was applied for the 22 data set. hPDE4B and
hPDE4D2 structures with NPD-001 (1) were solved by MR using
their respective apo models (PDB codes 3G45 and 3SL3,
respectively). Ligand descriptions were generated by ACEDRG
available within the CCP4 package35 or with the grade Web Server
(http://grade.globalphasing.org/). Adjustment of the models and
ligand ﬁtting were performed with COOT37 and reﬁnement with
REFMAC5.38 The ﬁnal structures had good geometry and could be
reﬁned to low R-factors (Tables S1 and S3). All reﬁned models were
validated with MOLPROBITY.39 Data collection and reﬁnement
statistics are given in Supplementary Tables S1−S4. Root-mean-square
(rms) deviation values were calculated from a sequence alignment,
structural superposition, and reﬁnement cycle on Cα carbons with the
align function as implemented in PyMOL 1.7.4.4 (The PyMOL
Molecular Graphics System, Schrödinger, LLC). All binding site
residues have been named according to the PDEStrIAn nomenclature
system (http://pdestrian.vu-compmedchem.nl/).21 Structural ﬁgures
were prepared with PyMOL 1.7.4.4. For clarity, selected residues from
the helix capping the substrate binding pocket (i.e., D784, M785,
A786, K787, H788, G789, S790, A791, L792, and E793 in TbrPDEB1;
D518, M519, S520, K521, H522, M523, S524, and L525 in hPDE4B;
D272, M273, S274, K275, H276, M277, N278, and L279 in hPDE4D)
have been omitted in the rendering of the ﬁgures. Coordinates of the
structures have been deposited to the RCSB Protein Data Bank with
following accession codes: 5G57 (TbrPDEB1−NPD-001); 5LAQ
(hPDE4B−NPD-001); 5LBO (hPDE4D−NPD-001); 5L9H
(TbrPDEB1−NPD-340); 5G2B (TbrPDEB1−NPD-008); 5L8C
(TbrPDEB1−NPD-039); 5G5V (TbrPDEB1−NPD-038); 5L8Y
(TbrPDEB1−NPD-937).
Molecular Dynamics. Molecular dynamics simulations of the
TbrPDEB1−NPD-008 (8) crystal structure (PDB code 5G2B) were
performed with GROMACS 5.1,40,41 using the Amber ﬀ99SB-ILDN
force ﬁeld42 and a TIP3P water model,43 running with MPI
parallelization. Ligand input ﬁles, based on 8 extracted from chain A,
were prepared with Antechamber as implemented in AmberTools14
(AMBER 14, University of California, San Francisco, 2014) by the
calculation of AM1-BCC partial charges, and generation of a GAFF
topology. Subsequent preparation of the parameters and ligand
topology was performed with LEaP. ACPYPE44 was used to convert
the ligand ﬁles to GROMACS input format. The protein−ligand
complex of 8 and chain A from TbrPDEB1, together with the Mg2+
and Zn2+ ions and the crystal water network directly coordinating the
binding site cations consisting of six crystal waters, was centered at
least 1.0 nm from the edges of a cubic box, that was fully solvated and
charge neutralized by the addition of Na+ ions. The system was energy
minimized with a steepest descent algorithm for 5000 steps with an
initial step size of 0.01 nm. Bonds were constrained with the P-LINCS
algorithm,45 an integration time step of 2 fs was used, and the smooth
particle mesh Ewald (PME) method was used for the calculation of
long-range electrostatics. The Verlet cutoﬀ scheme was used for
neighbor searching; cutoﬀ distances of 1.0 nm were set for the short-
range neighbor list as well as for Coulomb and van der Waals
interactions. Initial equilibration was performed in three 250 ps steps
by gradually increasing the temperature from 100 to 298 K while
decreasing the position restraint force constant from 1000 kJ mol−1
nm−1 to 500 kJ mol−1 nm−1 and ﬁnally to 50 kJ mol−1 nm−1. In the
canonical (NVT) ensemble, a velocity rescaling thermostat was used.
The Parrinello−Rahman barostat and a position restraint force
constant of 25 kJ mol−1 nm−1 was used in the isothermal−isobaric
(NPT) ensemble equilibration for 250 ps at 298 K and 1.0 bar. A ﬁnal
unrestrained equilibration step was executed for 500 ps at 298 K and
1.0 bar, followed by a production run of 100 ns. The ﬁrst 10 ns of the
simulation was omitted from analysis. The stability of the system and
the results of the simulations were validated and analyzed with gmx
rms, energy, gyrate, rmsf, distance, and hbond tools as implemented in
GROMACS 5.1.
Parasite Culturing for cAMP Measurements and Micros-
copy. Bloodstream forms of T. brucei Lister 427 were cultured in
Hirumi-9 (HMI-9) medium (Invitrogen), supplemented with 10%
heat inactivated fetal bovine serum (FBS; Gibco) in vented culture
ﬂasks (Corning), at 37 °C, in a 5% CO2 atmosphere, as described
previously.46
Intracellular cAMP Measurements. Intracellular cAMP was
measured as described previously,10 with minor changes. Brieﬂy, log-
phase bloodstream form trypanosomes were inoculated into HMI-9/
FBS media and incubated at 37 °C overnight. The cells were counted
and suspended in HMI-9/FBS at 2 × 106 cells/mL, which was divided
into 8 subcultures of 6 mL each. To each culture ﬂask, a small volume
of HMI-9 medium containing either NPD-001 (1) (positive control;
ﬁnal concentration 0.3 μM), pentamidine (a known trypanocide not
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01670
J. Med. Chem. 2018, 61, 3870−3888
3885
acting on cAMP signaling; ﬁnal concentration 0.025 μM), NPD-008
(8) (at 0.1, 0.33, 1, 3.3, and 10 μM), or no drug (negative control) was
added. The cultures were incubated under standard conditions (37 °C,
5% CO2) for 5 h, after which cell densities were determined in each
culture using a hemocytometer; 5 × 106 cells were transferred into
new tubes and collected by centrifugation at 1500g for 10 min at 4 °C.
Cell pellets were resuspended in 100 μL of 0.1 M HCl and left on ice
for 20 min to complete cell lysis. The samples were centrifuged in a
microfuge at 12 000g for 10 min at 4 °C, and the supernatants (cell
extracts) were stored at −80 °C for the determination of intracellular
cAMP. Each cAMP determination was performed in duplicate, data are
represented as the mean of four independent cAMP determinations
with the standard error of the mean (SEM) and were analyzed with
Student’s t-test, diﬀerences were considered signiﬁcant at P < 0.05,
with P values as indicated.
Microscopy and DAPI Staining. For the monitoring of the cell
cycle (division of nucleus, kinetoplast, and cells) and cellular
morphology, trypanosomes were stained with 4′,6-diamidino-2-
phenylindole (DAPI) and observed by ﬂuorescence microscopy as
described.47 Brieﬂy, a culture of T. brucei bloodstream forms was
inoculated at 2 × 105 cell/mL in the presence of 10 μM NPD-008 (8).
Samples for microscopy were taken at 0, 6, 12, and 24 h and
centrifuged at 2600 rpm for 10 min at 4 °C in a Heraeus Biofuge
centrifuge. Supernatant was decanted, and the pellet was washed with
phosphate-buﬀered saline (PBS), pH 7.4, resuspended in 20 μL of PBS
and spread on a microscope slide. The slides were air-dried and then
ﬁxed in 4% formaldehyde/PBS for 15 min. Slides were rinsed 3 times
with PBS after which the samples were mounted in VectaShield
(Vector Laboratories Inc., USA) mounting medium with DAPI.
Samples were imaged on an Axioskop II microscope (Zeiss, Inc.) and a
DeltaVision Core (AppliedPrecision).
Phenotypic Cellular Assays. For the cellular assays, the following
reference drugs were used as positive controls: suramin (Sigma-
Aldrich, Germany) for T. brucei (pIC50 = 7.4 ± 0.2, n = 5), and
tamoxifen (Sigma-Aldrich, Germany) for MRC-5 cells (pIC50 = 5.0 ±
0.1, n = 5). All compounds were tested at ﬁve concentrations (64, 16,
4, 1, and 0.25 μM) to establish a full dose-titration and determination
of the IC50 and CC50; data are represented as the mean of triplicate
experiments ± SD. The ﬁnal concentration of DMSO did not exceed
0.5% in the assays.
Antitrypanosomal Cellular Assay with T. brucei. Squib-427 strain
(suramin-sensitive) was cultured at 37 °C and 5% CO2 in HMI-9
medium, supplemented with 10% fetal calf serum (FCS). About 1.5 ×
104 trypomastigotes were added to each well, and parasite growth was
assessed after 72 h at 37 °C by adding resazurin. The color reaction
was read at 540 nm after 4 h, and absorbance values were expressed as
a percentage of the blank controls.
MRC-5 Cytotoxicity Cellular Assay. MRC-5 SV2 cells, originally
from a human diploid lung cell line, were cultivated in MEM,
supplemented with L-glutamine (20 mM), 16.5 mM sodium hydrogen
carbonate, and 5% FCS. For the assay, 104 MRC-5 cells/well were
seeded onto the test plates containing the prediluted sample and
incubated at 37 °C and 5% CO2 for 72 h. Cell viability was assessed
ﬂuorimetrically 4 h after the addition of resazurin. Fluorescence was
measured (excitation 550 nm, emission 590 nm), and the results were
expressed as percentage reduction in cell viability compared to control.
Statistical Analysis. Details of the applied statistical analyses are
provided with each experiment. No statistical methods were used to
predetermine the size of samples. The experiments were not
randomized, and the investigators were not blinded to allocation
during experiments or outcome assessment.
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